Recent Market Survey on Global Myelodysplastic Syndrome Industry Trend, Growth and Forecast 2015-2019

Researchmoz added Most up-to-date research on "Global Myelodysplastic Syndrome Market 2015-2019" to its huge collection of research reports.

Myelodysplastic syndrome is a group of hematologic disorders that arise in the bone marrow and spread into the blood. The syndrome is characterized by the inability of the hematopoietic cells produced in the bone marrow to attain maturity. Cytological dysplasia is a common feature of the syndrome, progressing to acute myeloid leukemia in about 30% of individuals with myelodysplastic syndrome. The disease is age-related, mostly affecting people aged 60 and above. Smoking, exposure to radiation, contact with chemicals such as benzene, genetic mutations, and chemotherapy can cause myelodysplastic syndrome.

Technavios analysts forecast the global myelodysplastic syndrome market to grow at a CAGR of 9.93% during the period 2015-2019.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=527262

Covered in this report

The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome market for 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used for treating myelodysplastic syndrome.

The report describes the market by region:

Americas: The US, Canada, Mexico, and Brazil

EMEA: The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE

APAC: Japan, China, Australia, Singapore, South Korea, and India

Technavio's report, Global Myelodysplastic Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

Celgene

Novartis

Otsuka

Other prominent vendors

Acceleron Pharma

Amgen

Astellas

Astex...